Hematologic Oncology | Specialty

End-of-Life Care Poor for Elderly Patients With AML

August 23rd 2017

Hospice enrollment is low and use of aggressive treatment is high for elderly patients with acute myeloid leukemia, a situation investigators called “suboptimal” in results from a retrospective study.

Dr. Trotman on BGB-3111 in Patients With Waldenstrom's Macroglobulinemia

August 23rd 2017

Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.

Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML

August 23rd 2017

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

Dr. Erba on Unique Characteristics of CPX-351 in AML

August 22nd 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Arsenic Trioxide Consolidation Effective in Pediatric Acute Promyelocytic Leukemia

August 21st 2017

Arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses

Crenolanib Shows Promise in AML Patients With Variant FLT3 Mutations

August 21st 2017

Eunice Wang, MD, discusses the next steps for crenolanib and other emerging FLT3 inhibitors in AML.

Dr. Roboz on Advancements on the Horizon in AML

August 18th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

Crizotinib Induces High Response Rates in Pediatric ALCL, IMT

August 18th 2017

In a small study of pediatric patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, treatment with 165 mg/m2 of crizotinib (Xalkori) was associated with an overall response rate of 83%

Gilteritinib Shows Consistent FLT3 Inhibition in Relapsed/Refractory AML

August 18th 2017

Gilteritinib, a selective TKI against FLT3, demonstrated a favorable safety profile and consistent FLT3 inhibition in adults with relapsed/refractory acute myeloid leukemia.

Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

August 17th 2017

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

FDA Approves Inotuzumab Ozogamicin for ALL

August 17th 2017

The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Speculation Mounts About Price Tag for Emerging CAR Therapies

August 17th 2017

Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad, where regulatory permissions are likely to come more slowly than in the United States.

CAR T Cells Show Promise in Relapsed/Refractory Hodgkin Lymphoma, ALCL

August 17th 2017

Researchers have determined that CD30-specific CAR T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma.

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16th 2017

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

Dr. Chavez Shares His Advice for Treating Patients With CLL

August 16th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.

The Future of Treatment in Follicular Lymphoma

August 15th 2017

Novel Therapies in FL: Benefits and Challenges

August 15th 2017

Combination Therapy's Role in Follicular Lymphoma

August 15th 2017

Impact of Copanlisib in Follicular Lymphoma

August 15th 2017

Considering the Value of PI3 Kinase Inhibitors in FL

August 15th 2017